These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 10775866

  • 1. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil.
    Grundmann-Kollmann M, Mooser G, Schraeder P, Zollner T, Kaskel P, Ochsendorf F, Boehncke WH, Kerscher M, Kaufmann R, Peter RU.
    J Am Acad Dermatol; 2000 May; 42(5 Pt 1):835-7. PubMed ID: 10775866
    [Abstract] [Full Text] [Related]

  • 2. Psoriasis and psoriatic arthritis in a patient with HIV: response to mycophenolate mofetil treatment.
    Forman SB, Higginson R, Garrett AB.
    J Drugs Dermatol; 2008 Oct; 7(10):972-3. PubMed ID: 19112763
    [Abstract] [Full Text] [Related]

  • 3. Mycophenolate mofetil in autoimmune and inflammatory skin disorders.
    Nousari HC, Sragovich A, Kimyai-Asadi A, Orlinsky D, Anhalt GJ.
    J Am Acad Dermatol; 1999 Feb; 40(2 Pt 1):265-8. PubMed ID: 10025760
    [Abstract] [Full Text] [Related]

  • 4. Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients.
    Geilen CC, Arnold M, Orfanos CE.
    Br J Dermatol; 2001 Mar; 144(3):583-6. PubMed ID: 11260019
    [Abstract] [Full Text] [Related]

  • 5. Widespread plaque psoriasis responsive to mycophenolate mofetil.
    Tong DW, Walder BK.
    Australas J Dermatol; 1999 Aug; 40(3):135-7. PubMed ID: 10439523
    [Abstract] [Full Text] [Related]

  • 6. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses.
    Kitchin JE, Pomeranz MK, Pak G, Washenik K, Shupack JL.
    J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):445-9. PubMed ID: 9308561
    [Abstract] [Full Text] [Related]

  • 7. Mycophenolate mofetil and skin diseases.
    Hartmann M, Enk A.
    Lupus; 2005 Sep; 14 Suppl 1():s58-63. PubMed ID: 15803935
    [Abstract] [Full Text] [Related]

  • 8. Plasma trough levels of mycophenolic acid do not correlate with efficacy and safety of mycophenolate mofetil in psoriasis.
    Daudén E, Sánchez-Peinado C, Ruiz-Genao D, García-F-Villalta M, Onate MJ, García-Díez A.
    Br J Dermatol; 2004 Jan; 150(1):132-5. PubMed ID: 14746627
    [Abstract] [Full Text] [Related]

  • 9. Psoriasis vulgaris treated successfully with mycophenolate mofetil.
    Haufs MG, Beissert S, Grabbe S, Schütte B, Luger TA.
    Br J Dermatol; 1998 Jan; 138(1):179-81. PubMed ID: 9536244
    [Abstract] [Full Text] [Related]

  • 10. [Preliminary results in the therapy of psoriatic arthritis with mycophenolate mofetil].
    Schräder P, Mooser G, Peter RU, Puhl W.
    Z Rheumatol; 2002 Oct; 61(5):545-50. PubMed ID: 12399882
    [Abstract] [Full Text] [Related]

  • 11. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases.
    Grundmann-Kollmann M, Korting HC, Behrens S, Kaskel P, Leiter U, Krähn G, Kerscher M, Peter RU.
    J Am Acad Dermatol; 1999 Jun; 40(6 Pt 1):957-60. PubMed ID: 10365927
    [Abstract] [Full Text] [Related]

  • 12. Mycophenolate mofetil (CellCept) for psoriasis: a two-center, prospective, open-label clinical trial.
    Zhou Y, Rosenthal D, Dutz J, Ho V.
    J Cutan Med Surg; 2003 Jun; 7(3):193-7. PubMed ID: 12704533
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis.
    Akhyani M, Chams-Davatchi C, Hemami MR, Fateh S.
    J Eur Acad Dermatol Venereol; 2010 Dec; 24(12):1447-51. PubMed ID: 20384673
    [Abstract] [Full Text] [Related]

  • 14. [Mycophenolate mofetil: a new immunosuppressive drug in dermatology and its possible uses].
    Geilen CC, Orfanos-Boeckel H, Offermann G, Orfanos CE.
    Hautarzt; 2000 Feb; 51(2):63-9. PubMed ID: 10743574
    [Abstract] [Full Text] [Related]

  • 15. Mycophenolate mofetil in dermatology.
    Orvis AK, Wesson SK, Breza TS, Church AA, Mitchell CL, Watkins SW.
    J Am Acad Dermatol; 2009 Feb; 60(2):183-99; quiz 200-2. PubMed ID: 19150270
    [Abstract] [Full Text] [Related]

  • 16. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, Bianchi L, Chimenti S.
    J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
    [Abstract] [Full Text] [Related]

  • 17. Infliximab in psoriasis and psoriatic arthritis.
    Papoutsaki M, Osório F, Morais P, Torres T, Magina S, Chimenti S, Costanzo A.
    BioDrugs; 2013 Jan; 27 Suppl 1():13-23. PubMed ID: 23990278
    [Abstract] [Full Text] [Related]

  • 18. Change of treatment from cyclosporin to mycophenolate mofetil in severe psoriasis.
    Davison SC, Morris-Jones R, Powles AV, Fry L.
    Br J Dermatol; 2000 Aug; 143(2):405-7. PubMed ID: 10951153
    [Abstract] [Full Text] [Related]

  • 19. Sequential study on the treatment of moderate-to-severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporin.
    Pedraz J, Daudén E, Delgado-Jiménez Y, García-Río I, García-Díez A.
    J Eur Acad Dermatol Venereol; 2006 Jul; 20(6):702-6. PubMed ID: 16836499
    [Abstract] [Full Text] [Related]

  • 20. Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis.
    Herrera J, Ferrebuz A, MacGregor EG, Rodriguez-Iturbe B.
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S218-25. PubMed ID: 17130265
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.